CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Fractyl Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Fractyl Health Inc
3 Van De Graaff Drive, Suite 200
Phone: (781) 902-8800p:781 902-8800 BURLINGTON, MA  01803  United States Ticker: GUTSGUTS
Business Summary
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Allan R.Will 69 8/1/2012 8/1/2012
President, Co-Founder, Chief Product Officer Jay D.Caplan 62 1/1/2022 1/1/2019
Chief Executive Officer, Co-Founder, Director HarithRajagopalan 47 1/1/2011 1/1/2011
9 additional Officers and Directors records available in full report.

Business Names
Business Name
FRACTYL
Fractyl Laboratories Ltd.
Fractyl Securities Corporation
GUTS

General Information
Number of Employees: 102 (As of 12/31/2023)
Outstanding Shares: 48,098,944 (As of 11/1/2024)
Shareholders: 101
Stock Exchange: NASD
Federal Tax Id: 273553477
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024